Status:

COMPLETED

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment

Lead Sponsor:

Revmatismesykehuset AS

Collaborating Sponsors:

Abbott

Conditions:

Rheumatoid Arthritis

Psoriatic Arthritis

Eligibility:

All Genders

18-80 years

Brief Summary

The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexat...

Eligibility Criteria

Inclusion

  • Males and females 18-80 years
  • Able and willing to give written informed consent, and to comply with the requirements of the study protocol.
  • Fulfilling the ACR 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis, or the diagnostic criteria by Moll and Wright for the diagnosis psoriatic arthritis, or the modified New York diagnostic criteria for ankylosing spondylitis.
  • Clinical indication for starting treatment with methotrexate, TNFalpha- inhibitor or combination therapy.
  • Use of reliable method of contraception for women with childbearing potential.

Exclusion

  • Lack of cooperativity
  • Positive serology for hepatitis B or C
  • History of positive HIV status.
  • History of tuberculosis or untreated tuberculosis.
  • PPD more than 15 mm in previously BCG immunized subjects. PPD 6 mm or more if not previously BCG immunized.
  • Histoplasmosis or Listeriosis
  • Persistent or recurrent infections
  • Any inflammatory disease of permanence not related to RA, PSA or AS.
  • Pregnancy or breast-feeding.
  • Use of prednisolone more than 10 mg daily for 2 weeks at inclusion.
  • Use of TNFalpha-inhibitor the last 4 weeks.
  • History of cancer.
  • Uncontrolled diabetes.
  • Congestive heart failure (Nyha 3-4)
  • Recent stroke (within 3 months)
  • Previous diagnosis or signs of central nervous system demyelinating disease.
  • Previously diagnosed immunodeficiency.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2012

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT00902005

Start Date

April 1 2008

End Date

August 1 2012

Last Update

November 21 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Lillehammer Hospital for Rheumatic Diseases

Lillehammer, Oppland, Norway, 2609

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment | DecenTrialz